An op-ed authored by AdvaMed President and CEO Scott Whitaker was published today in Morning Consult on the importance of COVID-19 diagnostic testing and the role AdvaMed’s new national testing supply registry will play in helping the federal and state governments create and manage COVID-19 diagnostic testing strategies.
Whitaker explains that the national testing supply registry is a product of collaboration between AdvaMed and 13 diagnostic companies – representing 95 percent of the testing market.
“If the road to recovery goes through testing, we believe this registry provides the map.”Scott Whitaker, President & CEO, AdvaMed
“The registry gathers and analyzes information from these diagnostic companies, along with publicly available data on daily tests performed, to create a centralized, standardized, and ‘living’ picture of our COVID-19 diagnostic supply,” writes Whitaker, “with the aim of bolstering coordination across a wide set of public and private sector entities working to increase testing availability.”
“If the road to recovery goes through testing,” Whitaker concludes, “we believe this registry provides the map.”
Medtech POV Podcast
Subscribe to Medtech POV with Scott Whitaker, a podcast covering the intersection of medtech and policy from every perspective.